Aptamer-siRNA chimera targeting RORγt in Th17 cells for topical therapy of psoriasis

Case ID:
1896
Web Published:
10/7/2015
Description:

Summary
Researchers at Oregon Health & Science University and at the Portland VA Medical Center have discovered and validated a novel aptamer-siRNA chimera targeting RORγt in Th17 cells for topical treatment of psoriasis.

Technology Overview
Th17 cells produce several inflammatory cytokines, including IL-17, IL-17F, IL-22 and IL-21 which all have been implicated in mediating the chronic inflammation that is characteristic of a number of autoimmune inflammatory diseases. These include rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, and type 1 diabetes mellitus.

The current technology is a composition that targets RORγt, which is required for the differentiation of Th17 cells, for the treatment of chronic inflammatory conditions.

Publication
Shi, X. et al., “Silencing RORγt in Human CD4+ T cells with CD30 aptamer-RORγt shRNA Chimera.” Sci Rep 9, 10375 (2019). Link

Licensing Opportunity
This technology is available for licensing.

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Travis Cook
Senior Technology Development Manager
Oregon Health & Science University
cooktr@ohsu.edu
Inventors:
Cong-Qiu Chu
Gang Wang
Keywords:
Therapeutics - Dermatology
© 2023. All Rights Reserved. Powered by Inteum